J&J in Risperal Settlement
Johnson & Johnson JNJ -1.35% said in a securities filing Thursday that it had reached an agreement in principle with the U.S. Justice Department and some states on settling investigations into marketing practices, including the illegal promotion of the antipsychotic Risperdal.
The New Brunswick, N.J., company didn’t give a dollar amount, which The Wall Street Journal has said could be as much as $2.2 billion depending on how many of the states suing the company join in.
In the filing, J&J said „issues remain open“ before the settlements are finalized, and some states may choose to opt out. It said Arkansas, Louisiana and South Carolina aren’t expected to participate in the settlements. More than 40 states and the District of Columbia have either sued J&J over Risperdal marketing or are investigating.